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The price of progress: Funding and financing Alzheimer’s disease drug
development
Jeffrey Cummingsa,*, Carl Reiberb, Parvesh Kumarb
aCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
bUniversity of Nevada, Las Vegas, NV, USA
Abstract Introduction: Advancing research and treatment for Alzheimer’s disease (AD) and the search for
effective treatments depend on a complex financial ecosystem involving federal, state, industry, advo-
cacy, venture capital, and philanthropy funding approaches.
Methods: We conducted an expert review of the literature pertaining to funding and financing of
translational research and drug development for AD.
Results: The federal government is the largest public funder of research in AD. TheNational Institute on
Aging, National Institute of Mental Health, National Institute of General Medical Sciences, and National
Center for Advancing Translational Science all fund aspects of research in AD drug development. Non-
National Institutes of Health federal funding comes from the National Science Foundation, Veterans
Administration, Food and Drug Administration, and the Center for Medicare andMedicaid Services. Ac-
ademic Medical Centers host much of the federally funded basic science research and are increasingly
involved in drug development. Funding of the “Valley ofDeath” involves philanthropy and federal funding
through small business programs and private equity from seed capital, angel investors, and venture capital
companies. Advocacy groups fund both basic science and clinical trials. The Alzheimer Association is the
advocacy organization with the largest research support portfolio relevant to AD drug development. Phar-
maceutical companies are the largest supporters of biomedical research worldwide; companies are most
interested in late stage de-risked drugs. Drugs progressing into phase II and III are candidates for pharma-
ceutical industry support through licensing, mergers and acquisitions, and co-development collaborations.
Discussion: Together, the funding and financing entities involved in supporting AD drug develop-
ment comprise a complex, interactive, dynamic financial ecosystem. Funding source interaction is
largely unstructured and available funding is insufficient to meet all demands for new therapies.
Novel approaches to funding such as mega-funds have been proposed andmore integration of compo-
nent parts would assist in accelerating drug development.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: NIH; NIGMS; NCATS; NIMH; NINDS; Venture capital; Advocacy; Philanthropy; Alzheimer’s disease; Clinical
trials; Pharmaceutical industry; Biotechnology companies; SBIR; STTR
Alzheimer’s disease (AD) is increasing in frequency as the
world’s population ages and poses a major threat to the pub-
lic health. AD doubles in frequency every 5 years after the
age 65, and the number of individuals in the United States
with AD dementia is projected to grow from a current 5.5
million to an estimated 14 million by the year 2050 [1,2].
The world’s population of AD dementia will increase from
35 million to an astonishing 135 million by 2050 [3]. The
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corresponding toll in human suffering and socioeconomic
costs will be enormous. The identification of milder forms
of cognitive impairment and preclinical AD further enlarges
considerations regarding the impact of AD on society
[2,4,5].
Prevention and treatment of AD by 2025 has been articu-
lated as a goal of the US government and has been endorsed
by other countries [6,7]. Prevention and treatment require
the development of new treatments that prevent or delay
the onset, slow the progression, or improve the symptoms
(cognitive, functional, and behavioral) of AD. The failure
rate of AD drug development is 99% [8]; the failure rate
of the development of disease-modifying therapies for AD
is 100%. Despite these discouraging outcomes in drug devel-
opment programs, the urgent need to address the socioeco-
nomic crisis posed by AD requires that we continue to
advance understanding of AD drug development. Lessons
learned from AD are likely to generalize to other neurode-
generative disorders (NDDs), given the many similarities
in protein aggregation and cell injury across NDD [9]. To
advance the research agenda in AD, financial resources are
required including funding from government, industry, ven-
ture capital, foundations, and philanthropy. Federal research
funding programs include the National Institutes of Health
(NIH), National Science Foundation (NSF), Food and
Drug Administration (FDA), Department of Defense, and
Veterans Administration (VA). Private sector funding in-
cludes sources in the biopharma industry, venture capital in-
vestments, foundations, advocacy organizations, and
support from philanthropists. Public-private partnerships
have formed to help ameliorate the financial burden to indi-
vidual entities, and industry collaborations have evolved to
de-risk investments [10,11]. Funding and financing
resources form a complex financial ecosystem, which is a
key to advancing research in AD. Here, we describe major
elements of this network of support especially as it
pertains to development of new drug treatments for AD.
1. Cost of AD drug development
Total costs of an AD drug development program are esti-
mated at $5.6 billion, and the process takes 13 years from
preclinical studies to approval by the FDA [12]. This com-
pares to an estimated cost of cancer treatment development
of $793.6 million per agent (assuming 9% cost of capital)
[13]. Considering the pharmaceutical industry as a whole
bringing a new agent to approval has an estimated cost of
$2.8 billion [14]. AD drug development costs substantially
exceed most estimates for drugs in other therapeutic areas.
Table 1 shows the average cost and duration of each phase
of AD drug development. These figures include the cost of
capital and the cost of failures that companies must sustain
if they work in the AD drug development arena. The high
rate of failure of AD drug development is partly responsible
for the high costs of advancing AD drug development [8],
but out-of-pocket costs for development of a single AD
agent approach $500 million (Table 1). Phase III trials are
the most costly part of AD drug development, and pharma-
ceutical companies are among the few enterprises that can
sustain such costs.
2. National Institutes of Health
The principle public funder of research is the US NIH, in-
vesting more in health research than any other public enter-
prise in the world with an annual budget of approximately
$34 billion U.S. dollars. The federal budget devoted to
NIH has had support from both Republican and Democratic
parties. There is a mismatch between the cost of disease to
society and the amount of research devoted to it. AD, for
example, costs the US society more than $216 billion annu-
ally, and it has an NIH budget of $1.8 billion; for every $1
spent on AD, less than 1% of that amount is devoted to
research [15,16]. AD has a greater impact on the US
economy than cancer or cardiovascular disease [15]; it has
a smaller NIH research budget than either of these disorders
(cancer – $6.0 billion, cardiovascular disease - $2.2 billion;
www.nih.gov).
Neuroscience research at NIH is guided by the Neurosci-
ence Blueprint and within that the NIH Neurotherapeutics
Blueprint was launched to create a virtual pharmaceutical
company aimed at advancing discovery and development of
small molecules to treat Central Nervous System disease
including NDDs [17]. The goal was to foster the development
of potential therapies in Academic Medical Centers (AMCs)
and biotechnology companies and to advance new therapies
to clinical trials and potential industry partnership. Once
funding is approved, lead discovery teams from the National
Institute of Neurological Disease and Stroke work collabora-
tively and guide the grantee’s development program. The lead
team assists in bioactivity/efficacy hit-to-lead studies, medic-
inal chemistry and lead optimization, pharmacokinetics and
toxicity, data management, manufacturing and formulation,
and phase 1 clinical trials [17].
Within the NIH, the major funding agency for AD
research is the National Institute on Aging (NIA). To support
Table 1
Cost and duration of each aspect of AD drug development
Stage of
process
Duration
(months)
Cost
(billions)* ($)
Cumulative out-of- pocket costs
(at end of each stage)
(millions) ($)
Preclinical 50.1 1.65
Phase I 12.8 1.19 71
Phase II 27.7 1.04 126
Phase III 50.9 1.79 413
FDA 18 0.02
Total 13.3 years 5.69
Abbreviations: AD, Alzheimer’s disease; FDA, Food and Drug Adminis-
tration.
*Capitalized and including cost of failures of drug development (from
Scott et al, 2014) [12].
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the development of new therapies for AD and related demen-
tias, the NIA funds a trial coordinating center—the Alz-
heimer Clinical Trial Consortium—that conducts clinical
trials on AD and related disorders and advances tools and
methods relevant to trials in this population. The NIA pro-
vides grant support for promising therapies to be tested
with the Alzheimer Clinical Trial Consortium and its trial
network. The Alzheimer Clinical Trial Consortium con-
tinues the themes of AD clinical trials initiated with the Alz-
heimer’s Disease Cooperative Study [18]. The NIA
participates in a public-private partnership—the Alz-
heimer’s Disease Neuroimaging Initiative (ADNI)—funded
partially by pharmaceutical companies and NIH whose goal
is to simulate a clinical trial and collect data relevant to trial
planning. The ADNI studies brain imaging and biomarker
changes in longitudinal cohorts of cognitively normal indi-
viduals, participants with mild cognitive impairment, and
mild AD dementia patients [19]. The ADNI has been very
scientifically productive and has produced publically avail-
able data relevant to calculating sample sizes needed to po-
wer clinical trials, the predictive value of biomarkers and
biomarker combinations, and the relationship of biomarkers
to clinical measures [20,21]. The ADNI is seen as a model of
research acceleration by a public-private partnership
[19,22].
The NIA has funded a project to create a Trial-Ready
Cohort for Preclinical and Prodromal AD to develop means
of enhancing recruitment of participants to clinical trials us-
ing electronic means, following them with serial on-line as-
sessments, and creating algorithms that help to predict which
among the registrants have positive amyloid scans required
for participation in AD clinical trials [23]. Other NIA pro-
grams relevant to AD drug development are shown in
Table 2.
The National Center for Advancing Translational Science
(NCATS) approaches disease states agnostically and empha-
sizes the development of methods, infrastructure, and collab-
orations applicable to all human diseases including AD. The
NCATS supports both preclinical and clinical aspects of drug
development [30]. Resources useful in preclinical drug devel-
opment are shown in Table 3 (www.ncats.nih.gov).
The NCATS Bridging Interventional Development Gaps
program enables research collaborations between individual
researchers and NCATS experts to generate preclinical and
clinical data through government contracts for use in Inves-
tigational New Drug applications to regulatory authorities
such as the FDA (www.ncats.nih.gov). Using the Bridging
Interventional Development Gap approach, the NIH out-
sources preclinical studies to contract research organizations
(CROs) under the direction of NCATS intramural re-
searchers with expertise in the relevant drug development
areas (Table 4).
The NCATS supports clinical translational research and
preclinical drug development (Table 5). The NCATS Clin-
ical and Translational Science Awards (CTSAs) form a
nationwide collaborative network of clinical trial sites that
advance clinical trial training and conduct trials on many
disease states [31–33]. The development of a single
institutional review board for trials is an example of an
initiative led by the NCATS and applied across the NIH to
facilitate trials [34].
The NCATS supports federal-pharmaceutical partner-
ships in the Accelerating Medicines Partnership to develop
agents within companies that have repositioning potential
[29]. These agents were originally intended for one indica-
tion but development was halted. Their mechanism of action
suggests that they may be useful in another condition, and
the NCATS supports these repositioning efforts in conjunc-
tion with the pharmaceutical company and AMC investiga-
tors. AD therapies are included in the Accelerating
Medicines Partnership [29].
The National Institute of General Medical Sciences
(NIGMS) supports research in AD and NDD as well as
many other disease states and normal physiology [35]. The
NIGMS comprises three scientific divisions including
Biophysics, Biomedical Technology, and Computational
Biosciences; Genetics and Molecular, Cellular, and Devel-
opmental Biology; and Pharmacology, Physiology, and Bio-
logical Chemistry and the Center for Research Capacity
Building. The NIGMS is responsible for basic science
research grants that explore new cellular pathways and
new laboratory methods, research training, and diversifica-
tion of the scientific workforce. The latter includes recruit-
ment and training of an ethnically diversified workforce as
well as leadership in funding programs and projects in states
that historically have received low levels of NIH funding and
have not had an opportunity to develop mature scientific pro-
grams, training, and resources [36].Work force development
in states with limited NIH funding is supported by the Insti-
tutional Development Award (IDeA) program. The IDeA
program includes Clinical Translational Research awards,
Center of Biomedical Research Excellence grants, and
IDeA Networks of Biomedical Research Excellence [37].
The Center for Neurodegeneration and Translational
Neuroscience, a collaboration between the Cleveland Clinic
Lou Ruvo Center for Brain Health (LRCBH) [38] and the
University of Nevada, Las Vegas, is supported by a Center
of Biomedical Research Excellence award and exemplifies
the support by the NIGMS of research in AD and NDD.
The Center for Neurodegeneration and Translational Neuro-
science comprises administrative, data management and sta-
tistics, and clinical and translational research cores, as well
as projects studying brain imaging and cognitive deficits in
AD and Parkinson’s disease and animal models of AD (see
accompanying articles in this e-book).
Research in AD may be part of the portfolio of other NIH
institutes. Research in behavioral issues in AD may be sup-
ported by the National Institute of Mental Health. An
example of National Institute of Mental Health-funded AD
research is the Clinical Antipsychotic Trials of Intervention
Effectiveness—Alzheimer’s Disease [39,40]. Similarly, a
study of ginkgo biloba for prevention of cognitive decline
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in older adults was supported by the National Center for
Complementary and Alternative Medicines [41].
Research funds are accessed through competitive grants
that support various types of research (Table 6). The NIH
grants include “direct costs” that cover the expenses of the
proposed research and “indirect costs” that are provided to
the institutions hosting the research to account for
research-related expenses not covered by the direct costs
including facilities, personnel management, and administra-
tion. These indirect costs can comprise up to 60% or more of
the total award and have become a major source of revenue
for research-intensive institutions [42]. This indirect support
is an essential part of the research ecosystem.
In addition to grants, the NIH supports small business ini-
tiations through Small Business Innovation Research and
Small Business Technology Transfer grants. These grants
are a key channel through which discoveries in academic
laboratories can be commercialized through small start-up
companies that begin the process of product development
with the aim of eventually partnering the agent, device, or
process for regulatory approval and commercialization.
The IDeA program sponsors four Regional Technology
Transfer Accelerator Hubs to facilitate development of
Small Business Innovation Research and Small Business
Technology Transfer applications from IDeA state investiga-
tors. The grants show the value of science in stimulating the
economy and creating jobs.
The NIH sponsors some large-scale trans-institute pro-
grams that address problems applicable to many institutes
and populations. The Brain Research through Advancing
Table 2
NIA-supported resources relevant to AD drug development
NIA-supported program Relevance to AD drug development
Alzheimer Clinical Trial
Consortium
Conducts clinical trials of AD treatments with an organized network of academic clinical trial sites
Alzheimer’s Disease
Neuroimaging Initiative
Longitudinal multisite study of biomarkers in preclinical AD, prodromal AD, andmild AD dementia in
a simulated trial structure [19–22]
Trial-Ready Cohort for
Preclinical and Prodromal AD
Study to identify how best to use innovative technologies to engage participants in clinical trials and
predict their biomarker status important for clinical trials [23]; conducted in partnership with GAP
AD Genetics Consortium Identify genes related to AD risk and progression and indicative of pathways amenable to treatment
[24]
National Cell Repository for AD Repository of biological material derived from AD and other NDD available for study to find disease
mechanisms that can be modified by treatment [25]
Dominantly Inherited AD Network Characterize the natural history of patients with autosomal dominant AD
DIAN-Treatment Unit (DIAN-TU) Conduct clinical trials in populations of participants with autosomal dominant AD mutations (funded
as a partnership with the Alzheimer’s Association) [26]
Alzheimer Prevention Initiative Conducts clinical trials in patients at high genetic risk of developing AD (funded as a public-private
partnership with pharmaceutical companies) [26]
Alzheimer’s Disease Centers Network of Centers that collect longitudinal data on AD and conduct AD research
National Alzheimer’s Coordinating Center Monitors, collects, archives, and provides access to data collected by the ADCs [27,28]
Alzheimer’s Drug Development Program Supports therapy development activities includingmedicinal chemistry, pharmacokinetics, absorption,
distribution, metabolism, excretion, toxicology efficacy in animal models, formulation
development, chemical synthesis under Good Manufacturing Practices, Investigational New Drug
enabling studies and initial phase I clinical testing.
Pilot Clinical Trials for the Spectrum of
Alzheimer’s Disease and Age-related
Cognitive Decline (PAR-18-175)
Funds development and implementation of phase I or II clinical trials of promising pharmacological
and nonpharmacological interventions in individuals with age-related cognitive decline and in
individuals with AD across the spectrum from pre-symptomatic to more severe stages of disease, as
well as to stimulate studies to enhance trial design and methods.
Phase III Clinical Trials for the Spectrum
of Alzheimer’s Disease and Age-related
Cognitive Decline (PAR-18-028)
Funds R01 grant applications that propose to develop and implement phase III clinical trials of
promising pharmacological and nonpharmacological interventions in individuals with age-related
cognitive decline and across the AD spectrum from presymptomatic to more severe stages of
disease.
AD Sequencing Project Whole genome and whole exome sequencing of genes relevant to AD (discovery and follow-up study)
Molecular Mechanisms of the Vascular
Etiology of Alzheimer’s Disease Consortium
Supports research to better understand how the vascular system may be involved in the onset and
progression of AD and related dementias.
Alzheimer’s Preclinical Efficacy Database (AlzPED) AlzPED provides tg model data across relevant translational criteria data sets such as therapeutic
agents and targets. AlzPED is designed to help identify the critical data, design elements, and
methodology missing from studies; making them susceptible to misinterpretation, less likely to be
reproduced, and reducing their translational value. Through this function, AlzPED is intended to
influence the development and implementation of reproducibility strategies, including guidelines
for standardized best practices for the rigorous preclinical testing of AD candidate therapeutics.
Accelerating Medicines Partnership-Alzheimer’s
Disease Target Discovery and Preclinical
Validation Project
The goal is to shorten the time between the discovery of potential drug targets and the development of
new drugs for AD treatment and prevention by integrating the analyses of large-scale molecular data
from human brain samples with network modeling approaches [29].
Abbreviations: AD, Alzheimer’s disease; NIA, National Institute on Aging; NDD, neurodegenerative disorders; GAP, Global Alzheimer Platform.
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Innovative Neurotechnologies initiative is one such activ-
ity. The Brain Research through Advancing Innovative
Neurotechnologies is supported by a partnership of the
NIH, NSF, Defense Advanced Research Projects Agency,
private foundations, and researchers [43]. The goal of the
Brain Research through Advancing Innovative Neurotech-
nologies is “to accelerate the development and application
of innovative technologies to construct a dynamic picture
of brain function that integrates neuronal and circuit activ-
ity over time and space” [44,45]. Understanding of brain
networks in AD will be among the many benefits of this
project.
3. Non-NIH federal funding
Non-NIH federal agencies have smaller research budgets
and grant portfolios related to AD. These agencies include
the NSF, VA, Department of Defense, FDA, Department of
Energy Office of Science, National Library of Medicine,
and Centers for Medicare and Medicaid Services.
The VA funds Geriatric Research, Education, and Clin-
ical Centers that support research projects in AD. The VA
projects that approximately 218,000 veterans will be diag-
nosed with dementia in 2017, an increase of more than
40,000 since 2008 and an urgent cause of concern for how
to best meet the needs of aging veterans.
The NSF has grants in Integrative Organismal Systems,
Molecular and Cellular Biosciences, and Computational Neu-
rosciences among many areas of investment (www.nsf.gov).
Some of these address issues important to understanding AD.
The FDA created the Critical Path Institute (C-Path)
which sponsors the Clinical Data Interchange Standards
Consortium and the Coalition Against Major Diseases
(CAMD). These enterprises develop strategies for data
interoperability and for qualification by the FDA of clin-
ical trial assessments and biomarkers. The CAMD led
the successful effort to qualify a simulation method of
AD clinical trials useful for trial planning [46]. The
CAMD also created the CAMD Online Data Repository
for AD consisting of standardized placebo group data
from 24 AD trials numbering 6500 subjects. The CAMD
Online Data Repository for AD represents a unique inte-
grated standardized clinical trial database whose size fa-
cilitates a comprehensive understanding of disease
heterogeneity and progression [47].
The Centers for Medicare and Medicaid Services funds
demonstration projects such as the Imaging Dementia: Evalu-
ating Amyloid Scanning study that is assessing the impact of
amyloid imaging on short- and long-term mild cognitive
impairment and AD patient outcomes. These data are critical
to decide whether amyloid imaging should be reimbursed by
the Centers for Medicare and Medicaid Services as part of
clinical care. Amyloid imaging is routinely used in clinical tri-
als and ImagingDementia: EvaluatingAmyloid Scanningwill
help in the translation of trial observations to clinical care.
The Department of Defense has funded imaging research
involving positron emission tomography and funds research
Table 3
NCATS resources for preclinical drug development
 Small molecules, compounds, and probes
B Assay Guidance Manual contains detailed information on developing appropriate assays for high-throughput screening projects
B Compound management team acquires chemical libraries for small molecule screening
B Clinical Genomics Center provides access to the NCATS pharmaceutical collection, a publicly available, web-based database with complete
information on 2508 drugs approved in the United States and a total of 8969 (as of 2011) agents worldwide that could be repurposed for treatment of
human disorders
B Chemical Genomics Center CurveFit serves as a public, stand-alone, and open-source version of the center’s own curve-fitting software, automatically
fitting and classifying observed dose-response curves
B PubChem contains a freely accessible database of small organic molecules and their activities in biological assays
B Phenotypic Drug Discovery Resource enables access to disease-relevant assays to explore the effects of small molecules on molecular processes
 Biomarkers
B Biomarkers, Endpoint, and Other Tools Resource hosts an online glossary developed by a FDA and NIH joint committee to clarify terms used in
translational science and medical product development
 Informatics tools and information systems
B Global Ingredient Archival System houses a registration system for the ingredients in medicinal products that makes it easier for stakeholders to
exchange information about substances in medicines, supporting scientific research on the use and safety of these products
Abbreviations: FDA, Food and Drug Administration; NIH, National Institutes of Health; NCATS, National Center for Advancing Translational Science.
Table 4
Components of the NCATS BrIDGs program
 Synthetic process development
 Scale-up and manufacture of active pharmaceutical ingredients
 Development of analytical methods
 Development of suitable formulations
 Pharmacokinetic/ADME studies, including bioanalytical method
transfer and validation
 Range-finding initial toxicology studies
 IND-enabling toxicology studies
 Manufacture of clinical trial supplies
 Product development planning and advice in IND preparation
Abbreviations: NCATS, National Center for Advancing Translational
Science; BrIDGs, Bridging Interventional Development Gaps; ADME, ab-
sorption, distribution, metabolism, and excretion; IND, investigational new
drug application.
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in traumatic brain injury and chronic traumatic encephalop-
athy relevant to AD.
4. State funding
Some states provide funds for AD centers or AD-related
research projects. For example, California funds California
Alzheimer’s Disease Centers and provides grant support for
research projects. Texas funds a Consortium of Alzheimer’s
Disease Centers, New York supports Centers for Excellence
for Alzheimer’s Disease, and the Nevada legislature has sup-
ported the Cleveland Clinic LRCBH that provides AD and Par-
kinson’s disease care and research in conjunction with the
Center for Neurodegeneration and Translational Neuroscience.
5. Academic Medical Centers
AMCs are key to innovation in understanding disease
biology, discovery of potential treatment interventions, and
initiation of projects that can lead to product commercializa-
tion including new drugs for prevention and treatment of
AD. AMCs have two main goals: teaching of the next gen-
eration of clinicians and biomedical scientists and discovery
of new knowledge by their clinical and scientific faculty. In
Table 5
Clinical drug development resources of NCATS
 Clinical and Translational Science Awards, a network of university-based clinical trial sites
 Accelerated Clinical Trial Agreement, a standardized contract model designed to reduce negotiation time and contracting delays for industry-sponsored
multisite clinical studies
 BEST Resource, an online glossary of terms used in translational science and medical product development
 ClinRegs, a public website that helps researchers navigate country-specific regulatory information as they plan and implement clinical trials
 Good Clinical Practice Social and Behavioral Research E-Learning Course, provides training for application of Good Clinical Practice principles to social
and behavioral research
 Streamlined, Multisite, Accelerated Resources for Trials IRB Reliance Platform, an umbrella agreement that establishes a harmonized approach for roles
and responsibilities of a single institutional review board (IRB) and participating sites
 PhenX Toolkit, well-established, broadly validated measures of phenotypic traits and environmental exposures of interest to investigators in human
genomics, epidemiology, and biomedical research
 REDCap, an easy-to-use, freely available tool for clinical study management and data capture
 ResearchMatch, a way to connect people who are trying to find research studies with researchers who are seeking people to participate in their studies
Abbreviations: NCATS, National Center for Advancing Translational Science; BEST, Biomarkers, Endpoint, and Other Tools Resource.
Table 6
Major NIH grant types (https://grants.nih.gov/grants/funding/ac_search_results.htm)
Grant title Grant number Grant description
Research Construction Programs C06 Research Facilities Construction Grant
Institutional Training and Director Program Projects DP1 NIH Director’s Pioneer Award
Institutional Training and Director Program Projects DP2 NIH Director’s New Innovator Awards
Institutional Training and Director Program Projects DP4 NIH Director’s Pathfinder Award - Multi-Year Funding
Research Career Programs K12 Physician Scientist Award (Program)
Research Career Programs K21 Scientist Development Award
Research Career Programs K23 Mentored Patient-Oriented Research Career Development Award
Research Program Projects and Centers P20 Exploratory Grants
Research Program Projects and Centers P30 Center Core Grants
Research Program Projects and Centers P50 Specialized Center
Research Projects R01 Research Project
Research Projects R13 Conference
Research Projects R21 Exploratory/Developmental Grants
Research Projects R33 Exploratory/Developmental Grants phase II
Research Projects R34 Planning Grant
Research Projects R41/42 Small Business Technology Transfer Grants—phase I and phase II
Research Projects R43/44 Small Business Innovation Research Grants—phase I and phase II
Research-Related Programs S06 Minority Biomedical Research Support-MBRS
Research-Related Programs S11 Minority Biomedical Research Support Thematic Project Grants
Research-Related Programs S21 Research and Institutional Resources Health Disparities Endowment
Grants -Capacity Building
Training Programs T32 Institutional National Research Service Award
Training Programs T37 Minority International Research Training Grants (FIC)
Cooperative Agreements U01 Research Project–Cooperative Agreements
Abbreviation: NIH, National Institutes of Health.
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the course of achieving their goals, AMCs deliver care to pa-
tients and are part of the health-care system.
Most basic science research conducted at AMCs is
funded by the NIH augmented by philanthropists, state fund-
ing, and biopharma partnerships. The pharmaceutical indus-
try has downsized its internal research capacities and
focused on late stage drug development and commercializa-
tion. To insure a steady flow of candidate compounds into
their pipelines, many pharmaceutical companies have forged
alliances with AMCs [48–54]. They fund AMC investigator
research in areas of mutual interest in return for access to
information, technology transfer, and commercialization
opportunities. AMCs protect the intellectual property of
the institution and the investigator through contractual
arrangements implemented by Technology Transfer
Offices [55,56]. A recent survey identified 78 AMC-based
drug discovery centers in the United States with 45 address-
ing neuropsychiatric and NDD targets [57]. The majority of
funding for these centers came from federal sources, but
some centers had substantive relationships with for-profit
enterprises, mostly pharmaceutical companies.
Investigators in AMCs “spin off” biotechnology start-ups
that typically focus on one promising compound, device, or
discovery that has commercial potential. The Small Busi-
ness Innovation Research and Small Business Technology
Transfer grants facilitate this process of initiating new
biotech start-ups. Angel funds, seed capital, and philan-
thropy assist AMC faculty in advancing the commercializa-
tion process. The spin-off companies are important sources
of innovative new drugs. Approximately half of recently
approved agents came from small biotechnology companies
and AMC laboratories [58–60]. An entrepreneurial spirit is
required to bridge the gap between academic culture and
attracting private funding in the quest to commercialize a
product. Products can be new drugs and treatments but
might also be biomarkers with commercial potential or
patentable processes that save time or money. Recently,
venture capital companies have begun to form
relationships directly with AMCs to encourage innovation,
support start-ups, and access new products moving toward
commercialization.
Fig. 1 provides an overview of how ideas for products
originating in AMCs generate financial support, leading to
eventual commercialization.
Adjustments are required by AMCs to facilitate drug
development by faculty. The AMC conflict of interest pol-
icies often impose stringent limitations on academic-
industry relationships and have the unintended consequence
of hindering the participation of academic investigators in
the drug discovery and development process [61,62]. As
industries increasingly turn to academic laboratories for
target identification and early-stage treatment candidate
development and to academic clinics for clinical trial leader-
ship and execution, conflict of interest rules must evolve and
be sufficiently flexible to allow AMC investigators to take
advantage of the opportunities offered through industry
collaboration while limiting influences that may be
perceived as inappropriate [49]. Similarly, recognition of
the important role of faculty involved in drug development
including industry-sponsored research through academic
promotion and award of tenure is critical to establishing a
culture of drug development in AMCs.
To enhance their role in AD drug discovery and develop-
ment AMCs need to provide students, residents, fellows,
doctoral candidates, and others interested in AD therapeutics
with courses, learning experiences, programs, and leader-
ship that will acquaint them with the drug development pro-
cesses and opportunities. The Stanford SPARK program
offers a model of how this can be achieved [63]. SPARK is
a hands-on training program in translational research
providing guidance and seed funds to teach how to develop
and commercialize drugs and diagnostics.
A major threat to AMC-industry collaboration is the lack
of reproducibility of many findings reported from academic
laboratories. Protocol errors, lack of statistical rigor in data
analysis, and inadequate reporting have resulted in poor
reproducibility and lack of confidence in research executed
in AMC laboratories [64]. Rigorous adherence to conduct
and reporting of basic and animal research is necessary to
restore confidence in academic laboratory reports and facil-
itate academic-industry collaborations [65].
6. Biotechnology companies and private equity
investment in AD drug development
Biotechnology companies can be defined as venture-
backed drug development firms using technological applica-
tions centered on biological systems, living organisms, or
their derivatives [66]. “Biotech” includes the disciplines of
genetics, molecular biology, biochemistry, embryology, and
cell biology and is linked to biomaterials, cell therapy, gene
therapy, immunotherapy/vaccines, protein therapeutics, and
some specialty pharmaceuticals and small-molecule thera-
peutics [66]. Success in AD drug development will produce
a very high return on investment. This possibility attracts
venture capital investment to AD research, but the high rate
of failure has kept this funding stream small [67]. Venture
capital investment in Central Nervous System disease
declined 40% in the 2009–2013 period compared with the
2004–2008 period [68]. Angel investors or seed capital pro-
viders have high risk tolerance and supply small amounts of
money to encourage novel ideas. If the concepts begin to
mature and promise to lead to a successful program, venture
capital may be attracted to allow more advanced drug devel-
opment. Venture capital funds are usually raised in “rounds”
of stock option sales (rounds A, B, and C) as milestones are
reached in the drug development process. Venture capital in-
vestors typically want relatively fast turn-around on their in-
vestment; exit strategies for venture capital investors include
transition of the biotech to partnerships, licensing agree-
ments, co-development or co-marketing agreements, and
progression to stock sales and initial public offerings. Venture
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capital investments available specifically to support AD drug
development include Dolby Family Ventures and the United
Kingdom-based Dementia Discovery Fund. Bill Gates of the
Gates Foundation recently contributed $50,000,000 to the
Dementia Discovery Fund and is providing $50,000,000 of
additional venture capital to encourage AD drug develop-
ment in the biotechnology sector [69].
Candidate therapies may pass from smaller to larger
biotech companies as biotechs seek to strengthen their pipe-
lines, progress toward vertically integrated Central Nervous
System companies, or attract investors interested in a
broader portfolio. This can be a healthy process allowing
drugs to progress in testing before major pharmaceutical
companies invest; however, the process also may lead to
abuse by passing flawed agents from company to company
and attracting capital from enthusiastic but under-informed
investors.
7. Advocacy organizations
The Alzheimer Association is the largest private noncor-
porate funder of AD research. In 2016, the association in-
vested $90 million in research, including $25 million in
new project investments and the rest in support of on-
going multi-year commitments [70]. The new project sup-
port included $7 million for clinical trials targeting brain
inflammation and $4.3 million for the Dominantly Inherited
AD Network-Treatment Unit [71] (Table 2).
The Alzheimer Foundation of America and UsAgain-
stAlzheimer’s support advocacy for AD funding and have
helped advance the national AD research agenda including
maintaining and increasing funding for AD research. UsA-
gainstAlzheimer’s helped advance the Global Alzheimer
Platform whose goal is to enhance recruitment and trial
conduct to accelerate AD drug development [23].
Advocacy plays a critical role in raising consciousness
about AD, referring patients to trials, supporting families,
providing research grants, and advocating for increased
funding. In some cases, advocacy collaborates directly
with laboratories or biotech companies to raise funds for
drug development [72,73].
8. Philanthropy
Philanthropists make contributions to advocacy organiza-
tions or directly to universities and scientists to support
research projects. Many philanthropists are motivated by
the experience of AD afflicting a family member, and
many family philanthropies have originated with the intent
of honoring a family member. Philanthropy plays a critically
important role in the AD research ecosystem. Philanthropy
often provides seed money for small projects that do not
yet have preliminary data that would support a federal grant
application. Philanthropy can fund high-risk/high-reward
projects that might be too risky to receive funding from other
sources such as the NIH.
The Alzheimer’s Drug Discovery Foundation (ADDF) is
a venture-philanthropy organization that is a key player and
innovator in the AD drug discovery and development land-
scape. The ADDF funds studies in animal models, provides
grants to fund animal toxicity testing of promising therapies,
and supports early-stage proof-of-concept clinical trials. The
venture philanthropy model allows the ADDF to take an
ownership position in early-stage companies they fund and
re-invest any revenues generated. Venture philanthropy is
being more commonly applied as a vehicle for collaboration
of foundation and advocacy groups with biotechnology com-
panies [74].
The Cleveland Clinic LRCBH is an AD care and research
organization in Las Vegas, Nevada [38]. It is a leader in drug
Fig. 1. Financial ecosystem beginning with discovery in an academic medical center (AMC) and progressing through biotechnology to the pharmaceutical
industry and eventually to market. Each stage of the process is supported by specific types of capital.
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development and clinical trials. The LRCBH was created
and continues to be supported by philanthropists. The
LRCBH demonstrates how philanthropy can influence a
community to develop resources for AD research, creating
a new AD research and drug development enterprise where
none existed previously. Once established, philanthropy-
based projects can attract federal funding and build clinical
trials programs to garner support from other sources. The
LRCBH now hosts a Center of Biomedical Research Excel-
lence award from NIGMS as well as other federal funding
and biopharma industry support. Multiple funding sources
are critical to the sustainability of an AD research organiza-
tion.
The Cure Alzheimer’s Fund and Bright Focus Foundation
are two philanthropies that provide grants to AD researchers
doing innovative research and have had a substantial influ-
ence on research progress.
FasterCures is a disease-agnostic organization promoting
information about drug development, conveningmeetings of
drug development stakeholders, and doing analyses of and
publishing novel means of advancing drug development
(e.g., patient engagement strategies). FasterCures has a Phi-
lanthropy Advisory Service that studies disease areas and
advises philanthropists on where investments will have
maximum impact. The Philanthropy Advisory Service con-
ducted such as analysis for AD [75].
9. Pharmaceutical industry
The pharmaceutical industry is the largest funder of drug
discovery and development research in the world, exceeding
that of NIH or any other funding organization. Biopharma
funds approximately 60% of all annual US research and
development activities. The total annual research and devel-
opment budget for biopharma (biotechnology and pharma-
ceutical industry) in 2016 was $75 billion [76]. Over 70%
of all AD clinical trials are sponsored or co-sponsored by
the pharmaceutical industry [77].
Payments from biopharma support much of the AD drug
development ecosystem. New agents may be accessed
through AMC collaborations, in-house discovery teams, ac-
quisitions of biotechnology companies, mergers with other
pharmaceutical companies, in-licensing of promising com-
pounds, and partnering and co-development arrangements.
Each of these has corresponding financial support by the
pharmaceutical company. Extensive in-house resources
and out-sourcing to CROs are needed for each aspect of
drug development—toxicity testing, manufacturing, supply
line management, site management, recruitment of partici-
pants to trials, regulatory affairs, and so on. Outsourcing to
CRO’s accounted for approximately $20 billion of the
2016 biopharma research and development budget. For
global drug development much of the infrastructure must
exist in each country in which the company supports
research activities [78].
Clinical trial sites are reimbursed for all activities pro-
vided to conduct biopharmaceutical trials, including trial
site start up, gaining the institutional review board permis-
sion, managing the drug supply, advertising for partici-
pants to enter the trial, conducting all assessments
(imaging, clinical interviews, rating scales, lumbar punc-
ture, and so on), providing all data to the sponsor, and
eventually closing the trial and maintaining records for
5 years after trial completion. Indirect payments (usually
in the range of 30%–35% of total costs) are provided to
the institutions hosting the research program. These pay-
ments comprise an important part of the financial infra-
structure of many research organizations conducting
clinical and translational research. All research must be
free of charge to participants.
10. Drug development ecosystem
Fig. 2 summarizes the interactions of the organizations
described previously to compose an ecosystem that supports
drug development for AD. Advancing new treatments is not
the only outcome on which the scientific enterprise is
brought to bear, but it is among the most important to
citizen-taxpayers who fund aspects of this work, and it
serves as an important example of the interaction of the pub-
lic and private sectors to improve public health.
The NIH is the principle supporter of investigator-
initiated research that leads to new targets and potential
new interventions. Pharmaceutical companies partner with
AMCs to support basic science research as they increasingly
divest themselves of in-house research laboratories.
Following optimization, the lead agent is tested for efficacy
in animal models to determine if effects in an animal model
system are supportive of the goals for the molecule. Animal
models have not predicted efficacy in humans, but advancing
an agent without knowledge of its effects in models would be
unwise [79]. Animal model assessments might be financed
through NIH funding to AMC investigators, by biotech-
nology companies, or by pharmaceutical companies.
Once there is sufficient confidence in efficacy at the ani-
mal model or test system level, the agent must be assessed
for toxicity and the range of doses safe in animals estab-
lished. Rodent and dog species are commonly used for
toxicity assessments. Financing this aspect of drug develop-
ment can be very difficult and comprises part of the “valley
of death,” where promising drugs stall because no funding is
available for this critically important step in new drug devel-
opment [22,80,81]. CROs exist to conduct these studies, and
other potential sources of support include the NIH NCATS
program. Biotechnology companies supported by venture
capital can fund this step if the investors are convinced of
the return on investment, and venture philanthropy such as
the ADDF has supported these studies.
Once safety and efficacy have been shown at the animal
level, the drug can be advanced to phase I first-in-human tri-
als. Phase I typically involves healthy volunteers to
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determine dose, tolerability, and pharmacokinetics of an
agent in humans. This phase also faces substantial funding
challenges and is part of the valley of death. The NIH may
support phase I trials through Clinical and Translational Sci-
ence Award programs. Biotechnology and pharmaceutical
companies may subcontract to CROs to perform the phase
I assessments using venture capital or internal budgets
generated by sales of other products. Pharmaceutical com-
panies prefer to engage in drug development in late phase
II or phase III but sometimes use partnership, in-licensing,
acquisition, or co-development strategies earlier in the
drug development process if the agent seems very likely to
succeed and has a good strategic fit with company objec-
tives. Phase II (learning trials to establish proof-of-concept
in patients with AD) is usually financed through biotech-
nology and pharmaceutical companies, and phase III (confir-
matory trials required to advance an agent to regulatory
review) is dominated by large pharmaceutical companies
although large- and medium-sized biotechnology companies
may sometimes advance agents through phase III and to reg-
ulatory approval. CROs are typically used to conduct phase
II and III trials; some pharmaceutical companies have in-
house trial execution capacity. Regulatory review prepara-
tion is typically led by in-house regulatory affairs teams,
but CROs with regulatory expertise are available to support
all or part of this process. Marketing of approved agents to
make the new treatment widely accessible to patients is per-
formed by pharmaceutical companies or the large- and mid-
sized biotechnology companies that have escorted the drug
through phase III trials and regulatory approval.
Ideally, the drug development process will produce prod-
ucts for FDA review that will eventually come to market
while also serving as a learning experience to generate
new agents as understanding of AD biology progresses.
Effective life cycle management of approved agents will
extend their use to new populations and new indications
(Fig. 3).
11. Innovations in financing translational research
The extreme expense of current drug development for AD
is not sustainable (Table 1), discourages companies from
working in the AD research arena, dissuades venture capital
from investing in AD drug development, and diminishes the
opportunity to advance new therapies for patients with AD.
Innovation is needed to improve the financial underpinnings
of AD drug development and translational research.
Modeling suggests that it will take an estimated $38.4
billion over a decade to deliver a robust pipeline of AD ther-
apeutics [82]. No single investment entity can undertake
Fig. 2. Drug development ecosystem: phases of drug development and sources of support for each phase. Abbreviations: ACTC, Alzheimer Clinical Trial Con-
sortium; BrIDGs, Bridging Interventional Development Gaps; BPN, Blueprint Neurotherapeutics Network; CRO, Contract Research Organization; CTSA,
Clinical and Translational Science Award; IDeA, Institutional Development Award from National Institute of General Medical Sciences (NIGMS); NCATS,
National Center for Advancing Translational Science; NIH, National Institutes of Health; SBIR, Small Business Innovation Research; STTR, Small Business
Technology Transfer grants.
J. Cummings et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 330-343 339
Downloaded for Anonymous User (n/a) at University of Nevada - Las Vegas from ClinicalKey.com by Elsevier on September 18, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
such a financial burden; a combination of federal and private
equity would allow the development of a mega-fund struc-
ture to cover the costs and underwrite AD therapeutic devel-
opment [83]. This would accommodate a high failure rate
and decrease the risk of the investment by distributing the
opportunity for success among multiple agents and allowing
parallel development of multiple treatment approaches.
Public-private partnerships are an effective means of
advancing research by distributing the cost among federal
and private sources [10,11,84,85]. This can be especially
effective in precompetitive arenas such as biomarker
development, disease modeling, and advancing analytics
[86]. As noted, the ADNI is an example of a very productive
research program jointly funded by the NIH and several
pharmaceutical companies.
A novel approach that has emerged involves venture
funding approaches adopted by some advocacy groups to
directly fund drug development [72].
Crowd funding is another innovation using web-based
means of raising funds. This has succeeded in generating
small amounts of funding to inaugurate new drug develop-
ment programs [87,88]. Crowd-sourcing of drug develop-
ment problems is another innovation using motivational
prizes to harness the creativity of web-connected individuals.
Collaboration of two or more pharmaceutical companies
is a means of distributing financial risk of AD drug develop-
ment. Co-development and risk sharing is an increasingly
popular strategy. Current examples include collaborative
development of a b-site amyloid precursor protein cleaving
enzyme inhibitor by Eli Lilly and AstraZeneca and co-
development of a b-site amyloid precursor protein cleaving
enzyme inhibitor and an anti-amyloid antibody by Eisai and
Biogen. The Alzheimer Prevention Initiative is an example
of collaboration among NIH, a private institute (Banner Alz-
heimer Institute), and two pharmaceutical companies [26].
Research centers poised at the interface of health-care
systems and academic universities and committed to
advancing treatment innovations represent another evolving
development that can advance drug development. The Ox-
ford Biomedical Research Center is an example [89].
Funding from the NIH, the Alzheimer’s Association, and
many other organizations is awarded on a competitive basis
with each application scored by scientific peers with funds
given primarily on the basis of the rank of the score. An alter-
native model is used by the Adelson Medical Research
Foundation. In this approach, a field-limiting problem is
identified by a group of experts, means of solving the prob-
lem are posed, and the quality of the proposed solutions re-
viewed. Skills and resources from several laboratories are
usually required to address the identified problem. All par-
ticipants must agree to collaborate and share data. Once
these requirements are fulfilled, all collaborators are funded.
More innovation in financial structures is needed to sus-
tain and accelerate AD drug development. In addition, the
ecosystem is relatively unstructured, lacking a comprehen-
sive roadmap for how to optimize and accelerate the process
of moving promising treatments through the pipeline. In
some cases, promising compounds are not supported while
flawed agents find funding and are advanced. The current
funding and financing ecosystem is too limited to advance
new therapies quickly enough to meet the needs of the bur-
geoning patient population.
12. Summary
AD research and treatment development requires exten-
sive capital. Funding from federal agencies, state appropria-
tions, private equity, philanthropy, and advocacy is needed to
achieve the goal of developing treatments to prevent, delay,
slow the progress, or improve the symptoms of AD. Given
the high cost of caring for these disorders and the projected
increase in the population of those affected, the investment
will more than repay itself in decreased costs, market reve-
nue, and improved quality of life for patients.
AD drug development must be accelerated to address the
unmet needs of the growing AD population. Greater collabo-
ration among stakeholders, more precompetitive cooperation
among industry members, more flexible AMC-industry
partnerships, greater investment in basic research to iden-
tify viable targets and biomarkers, improved preparation
of students for careers in drug discovery and development,
more open forums for exchange of ideas about promising
compounds, greater risk sharing in the expensive later
stages of drug development, and more innovation in drug
discovery/development financing can all contribute to
finding effective treatments urgently needed by those with
or at immanent risk of manifesting AD. The efficiency of
drug development must also be improved. Faster
Fig. 3. The drug development system envisioned as a cycle that develops
new products for FDA review and feeds back to the cycle for improved prod-
uct development. Abbreviation: FDA, Food and Drug Administration.
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assessment of drugs in nonclinical settings, improved bio-
markers to detect effects with smaller sample sizes, and
improved conduct of trials can all contribute to decreasing
costs of drug development [90,91].
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RESEARCH IN CONTEXT
1. Systematic review: Drug development for Alz-
heimer’s disease (AD) and neurodegenerative disor-
ders (NDD) has a high failure rate and the costs of
drug development are very high. These factors
combine to reduce interest in AD drug development
and discourage investment from venture capital,
biotechnology, philanthropy, and pharmaceutical
companies in AD therapeutic development. Under-
standing the financial ecosystem underpinning AD
drug development provides insights into this com-
plex process and suggests opportunities for improve-
ment.
2. Interpretation: Drug development typically begins
with National Institutes of Health (NIH)-supported
basic science research. These investigations might
be supported by National Institute on Aging, Na-
tional Institute of Neurological Disease and Stroke
(NINDS), or National Institute of General Medical
Sciences (NIGMS). Spinoffs and startups from aca-
demic laboratories are financed through small busi-
ness awards from the NIH, angel funding, or seed
monies from philanthropists and donors. Increasing
confidence in a drug through toxicity studies and an-
imal efficacy is supported by biotechnology com-
panies and venture capital. As compounds mature
into the clinical phase of testing, support from phar-
maceutical companies is typical although biotech-
nology companies and federal agencies can also
support advanced drug development.
3. Future directions: AD drug development depends on
a complex funding and financing ecosystem. Novel
mechanisms for funding drug development are
evolving and improvement in the efficacy of drug
development funding can accelerate the development
of new therapy for patients with AD and other NDD.
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